- Home
- CWEN vs FOLD Comparison
CWEN vs FOLD Comparison
Compare CWEN & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- FOLD
- Stock Information
- Founded
- CWEN 2012
- FOLD 2002
- Country
- CWEN United States
- FOLD United States
- Employees
- CWEN N/A
- FOLD N/A
- Industry
- CWEN Electric Utilities: Central
- FOLD Biotechnology: Pharmaceutical Preparations
- Sector
- CWEN Utilities
- FOLD Health Care
- Exchange
- CWEN Nasdaq
- FOLD Nasdaq
- Market Cap
- CWEN 3.1B
- FOLD 2.9B
- IPO Year
- CWEN 2013
- FOLD 2007
- Fundamental
- Price
- CWEN $25.97
- FOLD $9.76
- Analyst Decision
- CWEN Buy
- FOLD Strong Buy
- Analyst Count
- CWEN 7
- FOLD 8
- Target Price
- CWEN $30.86
- FOLD $17.00
- AVG Volume (30 Days)
- CWEN 751.0K
- FOLD 2.1M
- Earning Date
- CWEN 02-24-2025
- FOLD 02-26-2025
- Dividend Yield
- CWEN 6.34%
- FOLD N/A
- EPS Growth
- CWEN 124.49
- FOLD N/A
- EPS
- CWEN 1.04
- FOLD N/A
- Revenue
- CWEN $1,364,000,000.00
- FOLD $493,671,000.00
- Revenue This Year
- CWEN $9.13
- FOLD $34.80
- Revenue Next Year
- CWEN $7.39
- FOLD $20.83
- P/E Ratio
- CWEN $25.18
- FOLD N/A
- Revenue Growth
- CWEN 2.33
- FOLD 32.58
- 52 Week Low
- CWEN $20.63
- FOLD $8.79
- 52 Week High
- CWEN $30.92
- FOLD $14.03
- Technical
- Relative Strength Index (RSI)
- CWEN 49.85
- FOLD 56.57
- Support Level
- CWEN $25.08
- FOLD $9.39
- Resistance Level
- CWEN $26.18
- FOLD $9.80
- Average True Range (ATR)
- CWEN 0.78
- FOLD 0.25
- MACD
- CWEN 0.12
- FOLD 0.05
- Stochastic Oscillator
- CWEN 69.01
- FOLD 87.67
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into conventional power generation, renewables and thermal divisions.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.